Authors: Toledo, H Baly, A Castro, O Resik, S Laferte, J Rolo, F Navea, L Lobaina, L Cruz, O Miguez, J Serrano, T Sierra, B Perez, L Ricardo, ME Dubed, M Lubian, AL Blanco, M Millan, JC Ortega, A Iglesias, E Penton, E Martin, Z Perez, J Diaz, M Duarte, CA

Citation: H. Toledo et al., A phase I clinical trial of a mufti-epitope polypeptide TAB9 combined withMontanide ISA 720 adjuvant in non-HIV-1 infected human volunteers, VACCINE, 19(30), 2001, pp. 4328-4336

Authors: Tleugabulova, D Falcon, V Penton, E

Citation: D. Tleugabulova et al., Physico-chemical characterization of recombinant hepatitis B surface antigen by a multidimensional approach, J CHROMAT A, 845(1-2), 1999, pp. 171-179

Authors: Tleugabulova, D Falcon, V Penton, E Sewer, M Fleitas, Y

Citation: D. Tleugabulova et al., Aggregation of recombinant hepatitis B surface antigen induced in vitro byoxidative stress, J CHROMAT B, 736(1-2), 1999, pp. 153-166

Authors: Tleugabulova, D Falcon, V Penton, E

Citation: D. Tleugabulova et al., Evidence for the denaturation of recombinant hepatitis B surface antigen on aluminium hydroxide gel, J CHROMAT B, 720(1-2), 1998, pp. 153-163